SCHEMBL16092329

SCHEMBL16092329

CC(C)c1c(-c2ccc(OC(F)(F)F)cc2)[nH]c2c(C#N)cnn2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 12/20 0.55
▸ FNTA P49354 3/20 0.36
▸ FNTB P49356 3/20 0.36
▸ PGGT1B P53609 2/20 0.36
▸ NPBWR1 P48145 1/20 0.36
▸ MCHR1 Q99705 1/20 0.36
▸ LYN P07948 1/20 0.36
▸ RPS6KB1 P23443 1/20 0.36
▸ MARK3 P27448 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ STK3 Q13188 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ TAOK1 Q7L7X3 1/20 0.36
▸ AURKB Q96GD4 1/20 0.36
▸ KDM5C P41229 2/20 0.36
▸ KDM4C Q9H3R0 2/20 0.36
▸ KDM5B Q9UGL1 2/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ SCN10A Q9Y5Y9 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16092315 0.89 KDM5A (0.57) KDM5AFNTAFNTBPGGT1BDYRK1A
SCHEMBL16092251 0.88 SMN1; SMN2 (0.45) KDM5ANPBWR1MCHR1GSK3BKDM5C
SCHEMBL16092244 0.87 KDM5A (0.52) KDM5AKDM5CKDM4CKDM5BKDM6B
SCHEMBL16092331 0.86 KDM5A (0.42) KDM5AKDM5CKDM4CKDM5BKDM6B
SCHEMBL16092238 0.85 CSNK2A1 (0.39) KDM5AKDM5CKDM4CKDM5BKDM6B
SCHEMBL16092424 0.85 KDM5A (0.42) KDM5AFNTAFNTBPGGT1BPDE2A
SCHEMBL17547840 0.85 KDM5A (0.48) KDM5ANPBWR1MCHR1KDM5CKDM4C
SCHEMBL16092317 0.84 KDM5A (0.48) KDM5AKDM5CKDM4CKDM5BKDM6B
SCHEMBL16092242 0.84 KDM5B (0.44) KDM5AKDM5CKDM4CKDM5BKDM6B
SCHEMBL16092513 0.83 KDM5A (0.46) KDM5AKDM5CKDM4CKDM5BKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-03-03 — — US disclosed
WO-2015135094-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2015-09-17 — — WO disclosed
WO-2014139326-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035801-B2 Pyrazolo compounds and uses thereof KDM5A, KDM5C, KDM5B KDM5A 1/4885FNTA 4151/4885FNTB 3976/4885
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF KDM5A, KDM5C, KDM5B KDM5A 1/4885FNTA 4151/4885FNTB 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback